Opendata, web and dolomites

CVTVT SIGNED

A Non-Surgical Treatment to Restore Heart Valve Function

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CVTVT" data sheet

The following table provides information about the project.

Coordinator
CROIVALVE LIMITED 

Organization address
address: UNIT A GF, THE LIFFEY TRUST CENTRE, 117-125 UPPER SHERIFF STREET
city: DUBLIN
postcode: D01 Y0E7
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙735˙170 €
 EC max contribution 2˙494˙970 € (67%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CROIVALVE LIMITED IE (DUBLIN) coordinator 2˙494˙970.00

Map

 Project objective

'CroíValve is an innovative SME with the mission to lead the treatment of tricuspid valve disease and transform the lives of patients who currently face certain death.

In the US and EU, 550,000 patients present with tricuspid valve disease annually. Current treatment involves highly invasive, risky open-heart surgery and <1% receive this due to the risks involved. Recent clinical data is highlighting that the 'forgotten tricuspid valve' must be treated.

CroíValve has developed a non-invasive device uniquely tailored to the challenges of the tricuspid valve. It is a small device that is delivered through a vein into the right heart, restoring the function of the tricuspid valve. Invented by a leading cardiologist, and refined by expert biomedical engineers, CroíValve’s is a non-surgical, safe, effective, easy to use solution for treating all patients with TR. It will transform patients’ lives, provide physicians a safe and straightforward treatment option and reduce the hospitalisations.

There is a significant market potential of > €2.5Bn/year. With H2020 SMEi funding, this Phase 2 Innovation Proposal will support the activities necessary to complete clinical trials and demonstrate safety and efficacy for CE Mark approval. Securing this grant, alongside private funding, will enable the company to expand its manufacturing capabilities, build up its sales and marketing infrastructure. CroíValve’s management team have a successful track record in the development, patenting and commercialisation of medical devices who can position the company as a leader in the treatment of tricuspid valve disease.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CVTVT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CVTVT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More